denali news - Search News

Denali, ALS

Hosted on MSN · 2d

Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trial

The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.

Seeking Alpha · 17h

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click for my DNLI stock update.

MarketWatch · 3d

Denali Therapeutics Says ALS Trial Didn't Meet Endpoints

Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks. The biotechnology company said Monday that DNL343 didn't meet the primary endpoint of slowing disease progression as compared with a placebo.

Yahoo · 2d

Denali Reverses Its Fortunes With 'Too Early' Miss In ALS Treatment

Denali Therapeutics shares reversed higher on Tuesday after the drugmaker's ALS treatment failed in a six-month study.

Investor's Business Daily on MSN · 2d

Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.

Denali Therapeutics shares slumped for the second straight day Tuesday after the drugmaker's ALS treatment failed in a six-month study.

STAT1d

Denali Therapeutics spinout raises $200M as neuro company resets

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...

BioSpace8h

HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

ALS drugs from Denali, Calico come up short, marking setback for Healey trial

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

GMC Celebrates 25 Years Of The Denali

To commemorate the 25th anniversary of Denali, GMC is offering customers a special 25th Anniversary Denali Package available ...

Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected

Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data ...

BioSpace3d

Denali Suffers Another ALS Fail With Phase II/III Flop

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...

Denali Therapeutics: Strategic Pipeline Potential and Investment Opportunity Amid Recent Setbacks

Analyst Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price ...

13d

Trump Proposes Renaming Mount Denali to Mount McKinley, Sparking Cultural Debate

President-elect Donald Trump has announced plans to change the name of Mount Denali in Alaska back to Mount McKinley, ...

Hosted on MSN1d

Denali Fault Mystery Unveiled: A Geological Breakthrough Reshapes North America’s History

A 620-mile geological enigma that has baffled scientists for decades has finally been solved. The Denali Fault, a massive ...

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Denali, ALS

Related topics